The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in Portugal

Table 1 Incidences and Chi-squared based test for temporal trends in resistance

		2001–'02	2002–'03	2003–'04	2004–'05	2005–'06	P-value
Multidrug resistance
	n	33	30	22	21	13
	N	576	574	583	626	490
	incidence	5.7	5.2	3.8	3.4	2.7	0.003
	95%-CI	4.0 – 8.0	3.5 – 7.4	2.4 – 5.7	2.1 – 5.1	1.4 – 4.5
Full class resistance
NRTI	n	78	63	53	40	29
	N	576	572	578	619	476
	incidence	13.5	11,0	9.2	6.5	6.1	<0.001
	95%-CI	10.9 – 16.6	8.6 – 13.8	6.9 – 11.8	4.7 – 8.7	4.1 – 8.6
NNRTI	n	203	226	258	245	187
	N	570	557	541	560	445
	incidence	35.6	40.6	47.7	43.8	42.0	0.011
	95%-CI	31.7 – 39.7	36.5 – 44.8	43.4 – 52.0	39.6 – 48.0	37.4 – 46.8
PI	n	60	50	32	40	35
	N	574	570	572	611	479
	incidence	10.5	8.8	5.6	6.5	7.3	0.013
	95%-CI	8.1 – 13.2	6.6 – 11.4	3.9 – 7.8	4.7 – 8.8	5.1 – 10.0

NRTI, nucleoside reverse-transcriptase inhibitors; NNRTI, nonnucleoside reverse-transcriptase inhibitors; PI, protease inhibitors.
Multidrug resistance (MDR): at most 1 susceptible drug available over all classes; Full class resistance (FCR): no susceptible drugs available in a class.

ISSN: 1742-4690